DUBLIN–(BUSINESS WIRE)–Feb 3, 2021–
The "Biosimilar Hormones Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com’s offering.
Biosimilar hormones Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar hormones market.
Major players in the biosimilar hormones market are Teva Pharmaceutical, Gedeon Richter, Intas Pharmaceuticals, Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals and GC Pharma.
The global biosimilar hormones market is expected to decline from $2.05 billion in 2019 to $1.94 billion in 2020 at a compound annual growth rate (CAGR) of -5.18%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $4.10 billion in 2023 at a CAGR of 28.34%.
The biosimilar hormones market consists of sales of biosimilar hormones by entities that engage in manufacturing biosimilar hormones. These hormones are used when patients have a drop in hormones in their bodies or are unbalanced. Only goods and services traded between entities or sold to end consumers are included.
In March 2018, BRAIN AG, a technology company in the field of industrial biotechnology, developing microorganisms, natural substances and enzymes for industrial use, acquired Biocatalysts for an undisclosed amount. The strategic acquisition of a majority stake in Biocatalysts is intended to accelerate product-driven growth in the fast-growing specialty enzyme market and broaden the portfolio of the enzyme business of BRAIN. Biocatalysts is a US-based biotechnology company focused on the development, production and distribution of specialty enzymes for various industries such as food and fine chemicals.
The biosimilar hormones market covered in this report is segmented by type into teriparatide biosimilars; follitropin alfa biosimilars; insulin biosimilars; somatropin biosimilars; others and by application into research & biotechnology; diagnostics; biocatalysts; therapeutics; others.
Stringent regulations imposed on the approval of hormone biosimilars limits the growth of the biosimilar hormones market. Biosimilars are approved on the same standard of pharmaceutical quality, efficacy, and safety that apply to all biologics approved in the European Union. There should be a similarity between the biologics and biosimilars, and as the process of manufacturing differs, the approval process becomes expensive and likely hinders the growth of the biosimilar hormones market.
Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launch in untapped regions to make the drug accessible to a large population. The companies are focusing on launching their products across various locations to boost sales and maximize profits. For instance, in October 2019, Biocon Biologics and Mylan N.V. announced the launch of biosimilar hormones in Australia to treat the polygenic disorder.
The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market. The treatments required for hormone-related conditions are evolving over the years and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilars market.
Key Topics Covered:
1. Executive Summary
2. Biosimilar Hormones Market Characteristics
3. Biosimilar Hormones Market Size and Growth
3.1. Global Biosimilar Hormones Historic Market, 2015 – 2019, $ Billion
3.1.1. Drivers of the Market
3.1.2. Restraints on the Market
3.2. Global Biosimilar Hormones Forecast Market, 2019 – 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers of the Market
3.2.2. Restraints on the Market
4. Biosimilar Hormones Market Segmentation
4.1. Global Biosimilar Hormones Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Teriparatide Biosimilars
- Follitropin Alfa Biosimilars
- Insulin Biosimilars
- Somatropin Biosimilars
- Others
4.2. Global Biosimilar Hormones Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Research & biotechnology
- Diagnostics
- Biocatalysts
- Therapeutics
- Others
5. Biosimilar Hormones Market Regional and Country Analysis
5.1. Global Biosimilar Hormones Market, Split by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Biosimilar Hormones Market, Split by Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Companies Mentioned
- Teva Pharmaceutical
- Gedeon Richter
- Intas Pharmaceuticals
- Biocon
- Mylan
- Sanofi
- Sandoz (Novartis)
- LG Life Sciences
- Ferring Pharmaceuticals
- GC Pharma
For more information about this report visit https://www.researchandmarkets.com/r/sbenee
View source version on businesswire.com:https://www.businesswire.com/news/home/20210203005446/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/03/2021 06:28 AM/DISC: 02/03/2021 06:28 AM
http://www.businesswire.com/news/home/20210203005446/en
